Breakfast or fast? a trial puts Prifetrastat's absorption to the test

NCT ID NCT07731100

Not yet recruiting Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This phase 1 trial in 12 healthy adults tests whether eating a high-fat, high-calorie meal changes how much of the experimental drug prifetrastat enters the bloodstream. Each participant receives a single dose of prifetrastat once after a meal and once on an empty stomach, with a two-week break in between. The goal is to determine whether food affects drug levels, which could guide how prifetrastat is taken in future studies and by patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called prifetrastat (PF-07248144)
What this could lead to
If successful, this study could provide guidance on whether prifetrastat should be taken with or without food in future trials and for patients.
What could go wrong
This is a very early, small phase 1 study in just 12 healthy people, so results may not predict effects in patients or account for individual differences.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Pfizer Clinical Research Unit - New Haven

    New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.